Pharmacokinetic studies of AY4166 (4) - Metabolism of 14C-AY4166 in rats and dogs

R. Mihara, M. Suzuki, Y. Shima, M. Akiyoshi, N. Kondou, A. Gonsho

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Metabolism of the AY4166, a novel antidiabetic agent, was studied both in vive and in vitro. 1) When 14C-AY4166 was orally administrated to rats, a half of radioactivity detected in plasma at 0.5 hr after administration, accounted for the unchanged AY4166. The major metabolites in rat plasma were M1(25%), the methine hydroxylated product, M2 and M3(about 20% by mixture), the optical isomer of the methyl hydroxylated products. In the liver and kidney, major parts of radioactivity were presented as metabolites M1, M2 and M3. On the other hand, when 14C-AY4166 was orally administrated to dogs, more than 90% of radioactivity was presented as the unchanged AY4166 at 30 min and 4 hr. 2) After oral administration of 14C-AY4166 to rats, five metabolites were identified in the urine and the bile. The main metabolite excreted in urine was M1 (47.3%) followed by M2 and M3 and carboxyl derivatives, M9 and M10 which were supposed to be generated from M2 and M3 by oxidation. The main metabolites in bile were M9 and M10(43.1%) followed by M2 and M3 and M1. After oral administration of 14C-AY4156 to dogs, five more metabolites than rats were identified in the urine and in the bile. The major component excreted in bile was unchanged AY4166 followed by three glucuronic acid conjugates (M4, M5 and M6), dehydro derivative (M7), hydroxyl derivative (M8) and M9 and M10. 3) The interaction in vitro of AY4166 with MFO S9 fraction were studied using rat liver, kidney, duodenum, pancreas S9 fraction and plasma. In liver and kidney, three oxidative metabolites, M1, M2 and M3 and two carboxylic metabolites, M9 and M10 were formed, but in plasma, duodenum and pancreas no metabolite was formed. 4) Hypoglycemic effect of metabolites was compared with that of AY4166 in maximum blood glucose level reducing activity. It was observed; M1 was about five-six times less potent and M2 and M3 were three times less potent than AY4166, while M7 was almost as potent as AY4166.

Original languageEnglish
Pages (from-to)219-228
Number of pages10
JournalJapanese Pharmacology and Therapeutics
Volume25
Issue numberSUPPL. 1
Publication statusPublished - 1997

Fingerprint

Pharmacokinetics
Bile
Dogs
Radioactivity
Urine
Kidney
Duodenum
Hypoglycemic Agents
Oral Administration
Pancreas
Liver
Glucuronic Acid
Hydroxyl Radical
Blood Glucose
In Vitro Techniques

Keywords

  • Antidiabetic agent
  • AY4166
  • Metabolism

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Mihara, R., Suzuki, M., Shima, Y., Akiyoshi, M., Kondou, N., & Gonsho, A. (1997). Pharmacokinetic studies of AY4166 (4) - Metabolism of 14C-AY4166 in rats and dogs. Japanese Pharmacology and Therapeutics, 25(SUPPL. 1), 219-228.

Pharmacokinetic studies of AY4166 (4) - Metabolism of 14C-AY4166 in rats and dogs. / Mihara, R.; Suzuki, M.; Shima, Y.; Akiyoshi, M.; Kondou, N.; Gonsho, A.

In: Japanese Pharmacology and Therapeutics, Vol. 25, No. SUPPL. 1, 1997, p. 219-228.

Research output: Contribution to journalArticle

Mihara, R, Suzuki, M, Shima, Y, Akiyoshi, M, Kondou, N & Gonsho, A 1997, 'Pharmacokinetic studies of AY4166 (4) - Metabolism of 14C-AY4166 in rats and dogs' Japanese Pharmacology and Therapeutics, vol. 25, no. SUPPL. 1, pp. 219-228.
Mihara R, Suzuki M, Shima Y, Akiyoshi M, Kondou N, Gonsho A. Pharmacokinetic studies of AY4166 (4) - Metabolism of 14C-AY4166 in rats and dogs. Japanese Pharmacology and Therapeutics. 1997;25(SUPPL. 1):219-228.
Mihara, R. ; Suzuki, M. ; Shima, Y. ; Akiyoshi, M. ; Kondou, N. ; Gonsho, A. / Pharmacokinetic studies of AY4166 (4) - Metabolism of 14C-AY4166 in rats and dogs. In: Japanese Pharmacology and Therapeutics. 1997 ; Vol. 25, No. SUPPL. 1. pp. 219-228.
@article{0139634c14cb48b2a4c54e5e4dbc803b,
title = "Pharmacokinetic studies of AY4166 (4) - Metabolism of 14C-AY4166 in rats and dogs",
abstract = "Metabolism of the AY4166, a novel antidiabetic agent, was studied both in vive and in vitro. 1) When 14C-AY4166 was orally administrated to rats, a half of radioactivity detected in plasma at 0.5 hr after administration, accounted for the unchanged AY4166. The major metabolites in rat plasma were M1(25{\%}), the methine hydroxylated product, M2 and M3(about 20{\%} by mixture), the optical isomer of the methyl hydroxylated products. In the liver and kidney, major parts of radioactivity were presented as metabolites M1, M2 and M3. On the other hand, when 14C-AY4166 was orally administrated to dogs, more than 90{\%} of radioactivity was presented as the unchanged AY4166 at 30 min and 4 hr. 2) After oral administration of 14C-AY4166 to rats, five metabolites were identified in the urine and the bile. The main metabolite excreted in urine was M1 (47.3{\%}) followed by M2 and M3 and carboxyl derivatives, M9 and M10 which were supposed to be generated from M2 and M3 by oxidation. The main metabolites in bile were M9 and M10(43.1{\%}) followed by M2 and M3 and M1. After oral administration of 14C-AY4156 to dogs, five more metabolites than rats were identified in the urine and in the bile. The major component excreted in bile was unchanged AY4166 followed by three glucuronic acid conjugates (M4, M5 and M6), dehydro derivative (M7), hydroxyl derivative (M8) and M9 and M10. 3) The interaction in vitro of AY4166 with MFO S9 fraction were studied using rat liver, kidney, duodenum, pancreas S9 fraction and plasma. In liver and kidney, three oxidative metabolites, M1, M2 and M3 and two carboxylic metabolites, M9 and M10 were formed, but in plasma, duodenum and pancreas no metabolite was formed. 4) Hypoglycemic effect of metabolites was compared with that of AY4166 in maximum blood glucose level reducing activity. It was observed; M1 was about five-six times less potent and M2 and M3 were three times less potent than AY4166, while M7 was almost as potent as AY4166.",
keywords = "Antidiabetic agent, AY4166, Metabolism",
author = "R. Mihara and M. Suzuki and Y. Shima and M. Akiyoshi and N. Kondou and A. Gonsho",
year = "1997",
language = "English",
volume = "25",
pages = "219--228",
journal = "Japanese Pharmacology and Therapeutics",
issn = "0386-3603",
publisher = "Life Science Publishing Co. Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Pharmacokinetic studies of AY4166 (4) - Metabolism of 14C-AY4166 in rats and dogs

AU - Mihara, R.

AU - Suzuki, M.

AU - Shima, Y.

AU - Akiyoshi, M.

AU - Kondou, N.

AU - Gonsho, A.

PY - 1997

Y1 - 1997

N2 - Metabolism of the AY4166, a novel antidiabetic agent, was studied both in vive and in vitro. 1) When 14C-AY4166 was orally administrated to rats, a half of radioactivity detected in plasma at 0.5 hr after administration, accounted for the unchanged AY4166. The major metabolites in rat plasma were M1(25%), the methine hydroxylated product, M2 and M3(about 20% by mixture), the optical isomer of the methyl hydroxylated products. In the liver and kidney, major parts of radioactivity were presented as metabolites M1, M2 and M3. On the other hand, when 14C-AY4166 was orally administrated to dogs, more than 90% of radioactivity was presented as the unchanged AY4166 at 30 min and 4 hr. 2) After oral administration of 14C-AY4166 to rats, five metabolites were identified in the urine and the bile. The main metabolite excreted in urine was M1 (47.3%) followed by M2 and M3 and carboxyl derivatives, M9 and M10 which were supposed to be generated from M2 and M3 by oxidation. The main metabolites in bile were M9 and M10(43.1%) followed by M2 and M3 and M1. After oral administration of 14C-AY4156 to dogs, five more metabolites than rats were identified in the urine and in the bile. The major component excreted in bile was unchanged AY4166 followed by three glucuronic acid conjugates (M4, M5 and M6), dehydro derivative (M7), hydroxyl derivative (M8) and M9 and M10. 3) The interaction in vitro of AY4166 with MFO S9 fraction were studied using rat liver, kidney, duodenum, pancreas S9 fraction and plasma. In liver and kidney, three oxidative metabolites, M1, M2 and M3 and two carboxylic metabolites, M9 and M10 were formed, but in plasma, duodenum and pancreas no metabolite was formed. 4) Hypoglycemic effect of metabolites was compared with that of AY4166 in maximum blood glucose level reducing activity. It was observed; M1 was about five-six times less potent and M2 and M3 were three times less potent than AY4166, while M7 was almost as potent as AY4166.

AB - Metabolism of the AY4166, a novel antidiabetic agent, was studied both in vive and in vitro. 1) When 14C-AY4166 was orally administrated to rats, a half of radioactivity detected in plasma at 0.5 hr after administration, accounted for the unchanged AY4166. The major metabolites in rat plasma were M1(25%), the methine hydroxylated product, M2 and M3(about 20% by mixture), the optical isomer of the methyl hydroxylated products. In the liver and kidney, major parts of radioactivity were presented as metabolites M1, M2 and M3. On the other hand, when 14C-AY4166 was orally administrated to dogs, more than 90% of radioactivity was presented as the unchanged AY4166 at 30 min and 4 hr. 2) After oral administration of 14C-AY4166 to rats, five metabolites were identified in the urine and the bile. The main metabolite excreted in urine was M1 (47.3%) followed by M2 and M3 and carboxyl derivatives, M9 and M10 which were supposed to be generated from M2 and M3 by oxidation. The main metabolites in bile were M9 and M10(43.1%) followed by M2 and M3 and M1. After oral administration of 14C-AY4156 to dogs, five more metabolites than rats were identified in the urine and in the bile. The major component excreted in bile was unchanged AY4166 followed by three glucuronic acid conjugates (M4, M5 and M6), dehydro derivative (M7), hydroxyl derivative (M8) and M9 and M10. 3) The interaction in vitro of AY4166 with MFO S9 fraction were studied using rat liver, kidney, duodenum, pancreas S9 fraction and plasma. In liver and kidney, three oxidative metabolites, M1, M2 and M3 and two carboxylic metabolites, M9 and M10 were formed, but in plasma, duodenum and pancreas no metabolite was formed. 4) Hypoglycemic effect of metabolites was compared with that of AY4166 in maximum blood glucose level reducing activity. It was observed; M1 was about five-six times less potent and M2 and M3 were three times less potent than AY4166, while M7 was almost as potent as AY4166.

KW - Antidiabetic agent

KW - AY4166

KW - Metabolism

UR - http://www.scopus.com/inward/record.url?scp=0030759030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030759030&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 219

EP - 228

JO - Japanese Pharmacology and Therapeutics

JF - Japanese Pharmacology and Therapeutics

SN - 0386-3603

IS - SUPPL. 1

ER -